FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4312101659> ?p ?o ?g. }

• W4312101659 endingPage "376" @default.
• W4312101659 startingPage "367" @default.
• W4312101659 abstract "Abstract Veno-occlusive disease/sinusoidal obstruction syndrome (VOD/SOS) is a potentially life-threatening complication of haematopoietic cell transplantation (HCT) conditioning. The DEFIFrance post-marketing registry study evaluated effectiveness and safety in patients who received defibrotide. It collected retrospective/prospective patient data from 53 French HCT centres from July 2014 to March 2020. Primary endpoints were survival and complete response (CR; total serum bilirubin <2 mg/dL, multiorgan failure resolution) at Day 100 post-HCT among patients with severe/very severe VOD/SOS. A secondary endpoint was evaluation of treatment-emergent serious adverse events (TESAEs) of interest. Of 798 patients analysed, 251 and 81 received defibrotide treatment for severe/very severe VOD/SOS and mild/moderate VOD/SOS post-HCT, respectively; 381 received defibrotide for VOD/SOS prophylaxis. In patients with severe/very severe VOD/SOS post-HCT, Kaplan–Meier–estimated CR at Day 100 was 74% (95% confidence interval [CI]: 66%, 81%). At Day 100, 137/251 (55%) were alive and in CR. Kaplan–Meier–estimated Day 100 post-HCT survival was 61% (95% CI: 55%, 67%) in patients with severe/very severe VOD/SOS. TESAEs of interest occurred in 29% of these patients; VOD/SOS-related mortality at 12 months was 15%. DEFIFrance represents the largest collection of real-world data on post-registration defibrotide use, supporting the real-world utility of defibrotide for patients with severe/very severe VOD/SOS post-HCT." @default.
• W4312101659 created "2023-01-04" @default.
• W4312101659 creator A5000357619 @default.
• W4312101659 creator A5001526915 @default.
• W4312101659 creator A5004015988 @default.
• W4312101659 creator A5008084507 @default.
• W4312101659 creator A5009874901 @default.
• W4312101659 creator A5011668592 @default.
• W4312101659 creator A5014678847 @default.
• W4312101659 creator A5014782184 @default.
• W4312101659 creator A5024848689 @default.
• W4312101659 creator A5026906275 @default.
• W4312101659 creator A5029170546 @default.
• W4312101659 creator A5037455697 @default.
• W4312101659 creator A5040417184 @default.
• W4312101659 creator A5043485385 @default.
• W4312101659 creator A5050987906 @default.
• W4312101659 creator A5052502171 @default.
• W4312101659 creator A5058527857 @default.
• W4312101659 creator A5059968740 @default.
• W4312101659 creator A5062618437 @default.
• W4312101659 creator A5066352955 @default.
• W4312101659 creator A5073306699 @default.
• W4312101659 creator A5073698209 @default.
• W4312101659 creator A5080673678 @default.
• W4312101659 creator A5081937285 @default.
• W4312101659 creator A5086317399 @default.
• W4312101659 date "2022-12-23" @default.
• W4312101659 modified "2023-10-18" @default.
• W4312101659 title "Real-world use of defibrotide for veno-occlusive disease/sinusoidal obstruction syndrome: the DEFIFrance Registry Study" @default.
• W4312101659 cites W174830320 @default.
• W4312101659 cites W1779344217 @default.
• W4312101659 cites W1976869249 @default.
• W4312101659 cites W1993783426 @default.
• W4312101659 cites W1994552682 @default.
• W4312101659 cites W2066216766 @default.
• W4312101659 cites W2148164607 @default.
• W4312101659 cites W2180061107 @default.
• W4312101659 cites W2295805773 @default.
• W4312101659 cites W2342148351 @default.
• W4312101659 cites W2396687607 @default.
• W4312101659 cites W2462936585 @default.
• W4312101659 cites W2793137791 @default.
• W4312101659 cites W2803440649 @default.
• W4312101659 cites W2989005882 @default.
• W4312101659 cites W3011941691 @default.
• W4312101659 cites W3014544491 @default.
• W4312101659 cites W3017245290 @default.
• W4312101659 cites W3042280423 @default.
• W4312101659 cites W3165751127 @default.
• W4312101659 cites W4280621852 @default.
• W4312101659 doi "https://doi.org/10.1038/s41409-022-01900-6" @default.
• W4312101659 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36564486" @default.
• W4312101659 hasPublicationYear "2022" @default.
• W4312101659 type Work @default.
• W4312101659 citedByCount "1" @default.
• W4312101659 countsByYear W43121016592023 @default.
• W4312101659 crossrefType "journal-article" @default.
• W4312101659 hasAuthorship W4312101659A5000357619 @default.
• W4312101659 hasAuthorship W4312101659A5001526915 @default.
• W4312101659 hasAuthorship W4312101659A5004015988 @default.
• W4312101659 hasAuthorship W4312101659A5008084507 @default.
• W4312101659 hasAuthorship W4312101659A5009874901 @default.
• W4312101659 hasAuthorship W4312101659A5011668592 @default.
• W4312101659 hasAuthorship W4312101659A5014678847 @default.
• W4312101659 hasAuthorship W4312101659A5014782184 @default.
• W4312101659 hasAuthorship W4312101659A5024848689 @default.
• W4312101659 hasAuthorship W4312101659A5026906275 @default.
• W4312101659 hasAuthorship W4312101659A5029170546 @default.
• W4312101659 hasAuthorship W4312101659A5037455697 @default.
• W4312101659 hasAuthorship W4312101659A5040417184 @default.
• W4312101659 hasAuthorship W4312101659A5043485385 @default.
• W4312101659 hasAuthorship W4312101659A5050987906 @default.
• W4312101659 hasAuthorship W4312101659A5052502171 @default.
• W4312101659 hasAuthorship W4312101659A5058527857 @default.
• W4312101659 hasAuthorship W4312101659A5059968740 @default.
• W4312101659 hasAuthorship W4312101659A5062618437 @default.
• W4312101659 hasAuthorship W4312101659A5066352955 @default.
• W4312101659 hasAuthorship W4312101659A5073306699 @default.
• W4312101659 hasAuthorship W4312101659A5073698209 @default.
• W4312101659 hasAuthorship W4312101659A5080673678 @default.
• W4312101659 hasAuthorship W4312101659A5081937285 @default.
• W4312101659 hasAuthorship W4312101659A5086317399 @default.
• W4312101659 hasBestOaLocation W43121016591 @default.
• W4312101659 hasConcept C126322002 @default.
• W4312101659 hasConcept C141071460 @default.
• W4312101659 hasConcept C168563851 @default.
• W4312101659 hasConcept C197934379 @default.
• W4312101659 hasConcept C203092338 @default.
• W4312101659 hasConcept C2777408962 @default.
• W4312101659 hasConcept C2777712501 @default.
• W4312101659 hasConcept C2780895475 @default.
• W4312101659 hasConcept C2911091166 @default.
• W4312101659 hasConcept C44249647 @default.
• W4312101659 hasConcept C71924100 @default.
• W4312101659 hasConceptScore W4312101659C126322002 @default.
• W4312101659 hasConceptScore W4312101659C141071460 @default.
• W4312101659 hasConceptScore W4312101659C168563851 @default.

• next